Orgenesis Inc (ORGS)

[Cobra Kai]

looks like it might revisit the dollar mark if the volume continues to pour in


- 50,000 shares today- closing price .7484


(60- day average is only 3,454 per day- this one can really move with the right attention)

[Tommy]

I agree - volume precedes price

[Cobra Kai]

this one looks ready to breakout

[Tommy]

Product

http://www.orgenesis.com/technology/product

[Tommy]

Diabetes

http://www.orgenesis.com/market/diabetes

[Tommy]

Market

http://www.orgenesis.com/market/market-overview

[Tommy]

Profile

http://www.orgenesis.com/about-us/profile

[Justin]

tjodel, I just got mine today 3/19/2012

[satelliteguy]

Orgenesis changed its name and ticker from Business Outsourcing Services Inc. (BOUT). It's not the same company that used to be Organic Solutions.

This one has 1,750,000,000 authorized shares, so I'm expecting plenty of dilution.

[big time 21]

Just got a Hard mailer on this 1.1 Million Dollar Promo

[tjodel]

I just got one of those propaganda mailers about ORGS today.

It says that ORGS is now Orgenesis

March 13, 2012 09:00 AM Eastern Daylight Time
Orgenesis Inc. Announces Definitive Agreement to Acquire Autologous Insulin Producing Cells (AIPC) Regeneration Technology.

TEL AVIV, Israel--(BUSINESS WIRE)--Orgenesis Inc., (OTCBB: ORGS) (the “Company”) announced today that pursuant to a licensing agreement dated February 2, 2012 with Tel Hashomer - Medical Research, Infrastructure and Services Ltd. ("Tel Hashomer" or "THM), the Company has an exclusive license to develop and commercialize THM's rights in functional autologous insulin producing cells (AIPC) regeneration technology.

“THM), the Company has an exclusive license to develop and commercialize THM's rights in functional autologous insulin producing cells (AIPC) regeneration technology.”


This licensed portfolio is based on the groundbreaking work and two decades of research by the world renowned researcher, Prof. Sarah Ferber conducted at Tel Hashomer.

For the last thirteen years, Prof. Sarah Ferber, Ph.D in Medical Science, the head of the Molecular Endocrinology research unit at the Center for Regenerative Medicine, Stem Cells and Tissue Engineering, Tel Hashomer, has been developing this unique technology, which seeks to substitute malfunctioning organs with new functional tissues created from the patient's own existing organs. This technology employs a molecular and cellular approach directed at converting liver cells into functional insulin producing cells as a treatment for diabetes.

more: http://www.businesswire.com/news/home/20120313005456/en/Orgenesis-Announces-Definitive-Agreement-Acquire-Autologous-Insulin

[lifewarrior]

Morning,
i thought lady bugs killed fire ants..
Life

[fung_derf]

I was a dummy and this shall be my reminder.